Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.trsl.2021.02.010 http://scihub22266oqcxt.onion/10.1016/j.trsl.2021.02.010 33626415!7897406!33626415     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33626415&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Transl+Res 2021 ; 232 (?): 49-59 Nephropedia Template TP {{tp|p=33626415|t=2021. Inflammatory arthritis in patients with COVID-19 |pdf=|usr=}}{{33626415}} gab.com Text Inflammatory arthritis in patients with COVID-19 JO: Transl Res http://www.kidney.de/pget.php?&tw=1&pmid=33626415 #FOAvip Patients with inflammatory arthritis represent a possible high-risk group to COVID-19 due to their immunosuppressive regimen designed to maintain low disease activity. Thus, substantial effort has been put forth to understand the impact of COVID-19 on these patients. Patients with rheumatic diseases as a whole do not appear to be more susceptible to acquiring COVID-19. Furthermore, immunosuppression generally did not increase the likelihood of developing severe COVID-19, with the important exception of medium and high-dose glucocorticoid use. In addition, a small number of COVID-19 patients have developed new inflammatory arthritis; whether this represents an unmasking of previous subclinical disease or a bone fide virus-induced arthritis is unclear. Nevertheless, it appears that inflammatory arthritis patients currently on immunosuppression should continue their medication to prevent future flares and limit glucocorticoid usage. While this continues to be a rapidly evolving field, these data are reassuring to both patients with and providers treating inflammatory arthritides. Twit Text FOAVip Inflammatory arthritis in patients with COVID-19 ????Transl Res http://www.kidney.de/pget.php?&tw=1&pmid=33626415 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33626415 #FOAvip English Wikipedia <ref>{{Cite pmid|33626415}}</ref> Inflammatory arthritis in patients with COVID-19 #MMPMID33626415 Conway R; Konig MF; Graef ER; Webb K; Yazdany J; Kim AHJ Transl Res 2021[Jun]; 232 (?): 49-59 PMID33626415show ga Patients with inflammatory arthritis represent a possible high-risk group to COVID-19 due to their immunosuppressive regimen designed to maintain low disease activity. Thus, substantial effort has been put forth to understand the impact of COVID-19 on these patients. Patients with rheumatic diseases as a whole do not appear to be more susceptible to acquiring COVID-19. Furthermore, immunosuppression generally did not increase the likelihood of developing severe COVID-19, with the important exception of medium and high-dose glucocorticoid use. In addition, a small number of COVID-19 patients have developed new inflammatory arthritis; whether this represents an unmasking of previous subclinical disease or a bone fide virus-induced arthritis is unclear. Nevertheless, it appears that inflammatory arthritis patients currently on immunosuppression should continue their medication to prevent future flares and limit glucocorticoid usage. While this continues to be a rapidly evolving field, these data are reassuring to both patients with and providers treating inflammatory arthritides. |*SARS-CoV-2[MESH] |Arthritis/*etiology[MESH] |COVID-19/*complications[MESH] |Humans[MESH] |Immunosuppressive Agents/therapeutic use[MESH] |Rheumatic Diseases/drug therapy/*etiology[MESH]Inflammatory arthritis in patients with COVID-19 (epmc).pdf DeepDyve Pubget Overpricing